ClinicalTrials.gg
CompletedNCT01614457KONDUCTUpdated Feb 12, 2015Results posted

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

A Phase 3 interventional study of Ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 31 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2015-02-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
42nd of 84
70 · median 70
Started
2012
with 3 others
Phase 3
45 of 84
none open now
Registered
16th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 42nd largest by enrollment, is one of 4 that started in 2012, is one of 45 in phase 3, and was the 16th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.

Read the detailed description

Ivacaftor is the first CFTR modulator to show an improvement in CFTR function and clinical benefit in subjects with CF. Results from Phase 3 studies (VX08-770-102 [Study 102] [NCT00909532] and VX08-770-103 [Study 103] [NCT00909727]) showed that ivacaftor is effective in the treatment of subjects with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.

Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in subjects 6 years of age and older who have a G551D mutation in the CFTR gene.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF
  • Must have at least 1 allele of the R117H CFTR mutation
  • Percent predicted (FEV1) 40 percent (%) to 90% (for subjects aged 12 years or older) or 40% to 105% (for subjects aged 6 to 11 years) predicted normal for age, sex, and height
  • 6 years of age or older
  • Minimum weight of 15 kilogram (kg) at screening
  • Females of must not be pregnant
  • Willing to comply with requirements

Exclusion criteria

Exclusion Criteria:

  • CFTR gene mutation leading to CFTR channel with gating defect (that is, any 1 of the following mutations: G551D, G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D)
  • History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug
  • Abnormal liver function, at screening, defined as greater than or equal to (>=) 3 time (ULN), of any 3 or more of the following: serum (AST), serum alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum alkaline phosphatase (ALP), total
  • Colonization with organisms associated with a more rapid decline in pulmonary status (for example, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus) at screening
  • History of solid organ or hematological transplantation
  • History of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug
  • Ongoing participation in another therapeutic clinical study or prior participation in an drug study within 30 days before screening
  • Any "non-CF-related" illness within 2 weeks before Day 1 (first dose of study drug). "Illness" was defined as an acute (serious or non-serious) condition (for example, gastroenteritis)
  • Use of any inhibitors or inducers of cytochrome (CYP) P450 3A
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Ivacaftor

    Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.

    Drug: Ivacaftor

  • Placebo comparator
    Placebo

    Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.

    Drug: Placebo

Interventions

  • Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.

    Also known as: Kalydeco, VX-770

  • DrugPlacebo

    Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: Baseline, Week 24

  2. Change From Baseline in Sweat Chloride Through Week 24

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.

    Time frame: Baseline, Week 24

  3. Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

    The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life

    Time frame: Baseline, Week 24

  4. Time to First Pulmonary Exacerbation

    Number of events (pulmonary exacerbation) during the pre-specified time intervals were reported. A subject without an exacerbation before withdrawal from the study was considered censored at the time of withdrawal, and a subject without an exacerbation who completes the study period was considered censored at the end of the analysis period.

    Time frame: Day 0 to 15, Day 16 to 56, Day 57 to 112, Day 113 to 168

  5. Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence, including clinically significant clinical laboratory assessments which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: Baseline up to follow-up (3 to 4 weeks after last dose [last dose = Week 24])

07

Results

Posted Feb 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneIvacaftorPlacebo
Started3435
Completed3235
Not completed20
Withdrew: Non-compliance10
Withdrew: Pregnancy (self or partner)10

Outcome measures

PrimaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24
percent predicted of FEV1IvacaftorPlacebo
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 242.5724 ± 1.15320.4611 ± 1.1313
Statistical analysis
  • Ivacaftor vs Placebo · Mixed Model Repeated Measures · p = 0.1979 · Least squares (ls) mean difference: 2.1114 · 95% CI -1.1305 to 5.3532
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 24

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg/m^2
Change From Baseline in Body Mass Index (BMI) at Week 24
kg/m^2IvacaftorPlacebo
Change From Baseline in Body Mass Index (BMI) at Week 240.4910 ± 0.66530.2284 ± 0.6504
Statistical analysis
  • Ivacaftor vs Placebo · Linear Mixed model · p = 0.7780 (p-value for the treatment effect is from the slope of BMI (kg/m2) versus time (days).) · Ls mean difference: 0.2626 · 95% CI -1.5698 to 2.0950
SecondaryChange From Baseline in Sweat Chloride Through Week 24

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in Sweat Chloride Through Week 24
millimole per liter (mmol/L)IvacaftorPlacebo
Change From Baseline in Sweat Chloride Through Week 24-26.2771 ± 1.4584-2.3078 ± 1.3716
Statistical analysis
  • Ivacaftor vs Placebo · Mixed Model Repeated Measures · p = <0.0001 · Ls mean difference: -23.9693 · 95% CI -28.0094 to -19.9293
SecondaryChange From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24
units on a scaleIvacaftorPlacebo
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 247.5585 ± 2.2073-0.8289 ± 2.1569
Statistical analysis
  • Ivacaftor vs Placebo · Mixed Model Repeated Measures · p = 0.0091 · Ls mean difference: 8.3874 · 95% CI 2.1658 to 14.6090
SecondaryTime to First Pulmonary Exacerbation

Number of events (pulmonary exacerbation) during the pre-specified time intervals were reported. A subject without an exacerbation before withdrawal from the study was considered censored at the time of withdrawal, and a subject without an exacerbation who completes the study period was considered censored at the end of the analysis period.

Time frame:
Day 0 to 15, Day 16 to 56, Day 57 to 112, Day 113 to 168
Reported as:
Number · events
Time to First Pulmonary Exacerbation
eventsIvacaftorPlacebo
Day 0 to 1531
Day 16 to 5642
Day 57 to 11226
Day 113 to 16814
Statistical analysis
  • Ivacaftor vs Placebo · Cox Proportional Hazard Regression · p = 0.8556 · Hazard ratio (hr): 0.928
SecondaryNumber of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence, including clinically significant clinical laboratory assessments which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
Baseline up to follow-up (3 to 4 weeks after last dose [last dose = Week 24])
Reported as:
Number · participants
Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsIvacaftorPlacebo
Subjects with any AEs3235
Subjects with SAEs46

Adverse events

Collected over Baseline up to follow-up (3 to 4 weeks after last dose [last dose = Week 24]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor—4/34 (11.8%)32/34 (94.1%)
Placebo—6/35 (17.1%)35/35 (100%)
Most frequent serious events
Most frequent serious events
EventIvacaftorPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/346/35
CellulitisInfections and infestations1/340/35
ConstipationGastrointestinal disorders1/340/35
Most frequent other events
Showing 10 of 121
Most frequent other events
EventIvacaftorPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations11/3413/35
CoughRespiratory, thoracic and mediastinal disorders10/349/35
HeadacheNervous system disorders6/345/35
HaemoptysisRespiratory, thoracic and mediastinal disorders0/346/35
PyrexiaGeneral disorders2/346/35
Sputum increasedRespiratory, thoracic and mediastinal disorders5/344/35
Nasal congestionRespiratory, thoracic and mediastinal disorders5/342/35
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/342/35
DiarrhoeaGastrointestinal disorders5/344/35
Upper respiratory tract infectionInfections and infestations3/345/35

Baseline characteristics

Full Analysis Set (FAS) included all randomized subjects who received at least 1 dose of study drug (ivacaftor or placebo).

Age, Continuous
Age, Continuous(years)IvacaftorPlaceboTotal
Mean29.2 ± 16.5732.7 ± 17.4331.0 ± 16.98
Sex: Female, Male
Sex: Female, Male(Participants)IvacaftorPlaceboTotal
Female192039
Male151530
08

Study locations

31 sites
  • Birmingham, Alabama, United States
  • Palo Alto, California, United States
  • Hartford, Connecticut, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Lexington, Kentucky, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • St. Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Valhalla, New York, United States
  • Chapel Hill, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Madison, Wisconsin, United States
  • Belfast, United Kingdom
  • Edinburgh, United Kingdom
09

References and documents

Publications

  • Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9. PubMed 26070913 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 4 months after primary completion. A results delay was requested in Oct 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 8, 2012
Start
Jul 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Oct 31, 2014
Results first posted
Feb 12, 2015
Last update
Feb 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01614457
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Jun 8, 2012
Start date
Jul 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Feb 12, 2015
Last update
Feb 12, 2015

Study contacts

Richard Moss, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion